A real-world AI-based infrastructure for screening and prediction of progression in age-related macular degeneration (AMD) providing accessible shared care
MEDIZINISCHE UNIVERSITÄT WIEN
The Medical University of Vienna is one of Europe’s leading medical research institutions, renowned for its pioneering work in a wide array of biomedical sciences. With a strong emphasis on translational research, MedUni Wien focuses on transforming fundamental discoveries into innovative treatments and therapies that address major global health challenges, including cancer, cardiovascular disease, neurological and ophthalmic disorders. Its research initiatives are supported by cutting-edge facilities, including state-of-the-art imaging, genetics, and biomarker laboratories, which empower scientists to explore complex mechanisms of disease at molecular, cellular, and systemic levels. MedUni Wien actively participates in international research networks and clinical trials, positioning it as a global leader in advancing medical knowledge and translating findings directly into improved patient care.
Role in I-SCREEN
MedUni Wien offers unique synergies in medical and AI research. It hosts the interdisciplinary OPTIMA team under the leadership of Prof. Ursula Schmidt-Erfurth. Most importantly, the OPTIMA lab is recognized as the pioneer of AI-based image analysis for precision medicine in retinal disease, specifically age-related macular degeneration (AMD). Prof. Ursula Schmidt-Erfurth is a world-renowned retinal expert leading the retinal imaging group. She is the initiator and coordinator of the I-SCREEN project. Her team will oversee and contribute to the clinical research with emphasis on implementing AI tools into real-world patient care. Prof. Hrvoje Bogunović, based at the MedUni Wien Institute for Artificial Intelligence, is an expert in AI, and leads the technical developments of deep learning models with applications in ophthalmology. His team will be responsible for the development of predictive models for AMD progression (WP2).Team Members



